Quality Manager & Designated Individual

Company: Cure Talent
Apply for the Quality Manager & Designated Individual
Location: Thatcham
Job Description:

Cure Talent is delighted to be supporting an advanced surgical skills centre delivering world-class education and development to the orthopaedics sector.

As part of their continued growth, they are seeking a Quality Manager & Designated Individual to take full responsibility for their Human Tissue Authority licence.

This is a rare opportunity to take ownership of compliance, lab quality systems, and regulatory oversight for a cutting-edge anatomy lab used for surgical training and demonstration.

You will:

  • Act as the Designated Individual under the Human Tissue Authority, ensuring compliance with licensable activities, third-party agreements, and governance protocols.
  • Maintain and develop the Quality Management System, including SOPs, risk assessments, audits, and compliance documentation.
  • Oversee traceability, storage, and use of all human tissue, ensuring adherence to HTA requirements.
  • Lead on HTA inspections, internal audits, and staff training across all licensable activities.
  • Advise internal stakeholders on all matters relating to the HTA in support of new initiatives, lab operations, and continuous improvement.
  • Take responsibility as the Radiation Protection Supervisor.

You will need:

  • Strong experience working within HTA-regulated environments, with a clear understanding of the regulations and inspection processes.
  • Proven Quality Management background, ideally within medical devices, biosciences, or healthcare.
  • A relevant qualification in biological or medical sciences, or equivalent practical experience.
  • Excellent communication and stakeholder engagement skills.
  • High attention to detail and strong analytical problem-solving ability.

If you’re looking for an exciting opportunity to be part of a rapidly expanding company at the forefront of health technology innovation, get in touch today!

Posted: April 26th, 2025